Johannes Lubke

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology
Published: June 21, 2026

Cardio-Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies.

Cardio-Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies.

Journal: Journal of the American Heart Association
Published: June 09, 2026

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Journal: Frontiers in immunology
Published: May 07, 2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology
Published: March 15, 2026

Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis.

Myeloid Neoplasms With a t(5;12)(q31;p13) and an Associated ETV6::ACSL6 Gene Fusion Are Diagnostically Challenging and Have a Poor Prognosis.

Journal: Genes, chromosomes & cancer
Published: January 21, 2026

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

Journal: The journal of allergy and clinical immunology. In practice
Published: July 07, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances
Published: June 20, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances
Published: June 20, 2025

Leukocytosis, Monocytosis, and Eosinophilia in Systemic Mastocytosis: Analysis of Phenotype, Genetics and Prognosis in 596 Patients From the GREM Registry.

Leukocytosis, Monocytosis, and Eosinophilia in Systemic Mastocytosis: Analysis of Phenotype, Genetics and Prognosis in 596 Patients From the GREM Registry.

Journal: The journal of allergy and clinical immunology. In practice
Published: May 23, 2025

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Journal: British journal of haematology
Published: May 07, 2025

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Journal: Leukemia research
Published: April 18, 2025

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Journal: Scientific reports
Published: March 29, 2025
Showing 1-12 of 38

Last Updated: 09/26/2026